Pharmaceuticals - Europe

  • Europe
  • In 2024, the projected revenue in the Pharmaceuticals market in Europe is expected to reach €182.20bn.
  • The largest market within this market is Oncology Drugs, which is projected to have a market volume of €31.77bn in 2024.
  • Over the period from 2024 to 2029, the revenue is expected to show a compound annual growth rate (CAGR) of 4.75%, resulting in a market volume of €229.80bn by 2029.
  • When compared globally, United States is projected to generate the highest revenue, with €584.50bn in 2024.
  • Germany's pharmaceutical market is experiencing a surge in research and development, with a focus on innovative therapies and personalized medicine.

Key regions: United States, China, Germany, Japan, Europe

 
Mercado
 
Región
 
Comparación de regiones
 
Moneda
 

Analyst Opinion

The Pharmaceuticals market in Europe has been developing rapidly in recent years, with several trends and developments shaping the industry.

Customer preferences:
In Europe, customers are increasingly demanding personalized medicines that are tailored to their specific needs. This trend is driven by advancements in technology, which allow for more precise diagnosis and treatment of diseases. Furthermore, customers are also seeking out natural and organic products, which are perceived to be safer and more environmentally friendly.

Trends in the market:
In Germany, the Pharmaceuticals market is dominated by generic drugs, which account for the majority of sales. This is due to the country's strict regulations on drug pricing, which has led to a highly competitive market. In France, the market is characterized by a large number of small and medium-sized enterprises, which specialize in niche areas such as rare diseases and oncology. The UK, on the other hand, has a highly centralized market, with a few large companies dominating the industry.

Local special circumstances:
In Italy, the Pharmaceuticals market is heavily regulated by the government, which sets the prices of drugs. This has led to a highly fragmented market, with many small companies competing for market share. In Spain, the market is characterized by a high level of innovation, with many companies investing heavily in research and development. This has led to the country becoming a hub for biotech startups.

Underlying macroeconomic factors:
The Pharmaceuticals market in Europe is influenced by several macroeconomic factors, including population demographics, healthcare spending, and government policies. With an aging population, there is a growing demand for drugs that treat chronic conditions such as diabetes and heart disease. Furthermore, as healthcare spending continues to rise, governments are looking for ways to control costs, which has led to increased regulation of drug pricing. Finally, with the UK's exit from the EU, there is uncertainty about the future of drug regulation in Europe, which could have significant implications for the industry.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Visión general

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Espere, por favor

Contacto

¿Alguna duda? Estaremos encantados de atenderte.
Statista Locations
Contacto Nerea Marcos
Nerea Marcos
Client Success Manager

Lu - vi, 9:30 - 17:00 h (CET)

Contacto Meredith Alda
Meredith Alda
Sales Manager– Contacto (Estados Unidos)

Lu - vi, 9:00 - 18:00 h (EST)

Contacto Yolanda Mega
Yolanda Mega
Operations Manager– Contacto (Asia)

Lu - vi, 9:00 - 17:00 h (SGT)

Contacto Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contacto (Asia)

Lu - vi, 10:00 - 18:00 h (JST)

Contacto Lodovica Biagi
Lodovica Biagi
Director of Operations– Contacto (Europa)

Lu - vi, 9:30 - 17:00 h (GMT)

Contacto Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contacto (América Latina)

Lu - vi, 9:00am-6:00pm (EST)